R344
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 92
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.520
- PANCREAS_BETA_CELLS+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- INFLAMMATORY_RESPONSE+0.420
- KRAS_SIGNALING_DN+0.340
- TNFA_SIGNALING_VIA_NFKB+0.340
- IL6_JAK_STAT3_SIGNALING+0.330
- KRAS_SIGNALING_UP+0.330
- ALLOGRAFT_REJECTION+0.300
- COAGULATION+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.580
- OXIDATIVE_PHOSPHORYLATION-0.560
- PROTEIN_SECRETION-0.470
- MYC_TARGETS_V1-0.460
- DNA_REPAIR-0.400
- NOTCH_SIGNALING-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.350
- MITOTIC_SPINDLE-0.320
- FATTY_ACID_METABOLISM-0.290
- PEROXISOME-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1358561 | GTEX | — | 0.922 |
| 2 | BS_HHPA8NJ2 | Med | Medulloblastoma | 0.921 |
| 3 | SRR1414424 | GTEX | — | 0.913 |
| 4 | SRR1322456 | GTEX | — | 0.912 |
| 5 | MNG272 | — | — | 0.912 |
| 6 | SRR602271 | GTEX | — | 0.908 |
| 7 | MNG1146 | — | — | 0.908 |
| 8 | SRR607445 | GTEX | — | 0.906 |
| 9 | SRR1378841 | GTEX | — | 0.900 |
| 10 | SRR1362464 | GTEX | — | 0.900 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.520 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.520 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.230 | Idelalisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.110 | Inavolisib | — uncovered |